Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment ; volume:12 ; number:3 ; day:8 ; month:6 ; year:2010 ; pages:1-8 ; date:6.2010
Arthritis Research & Therapy ; 12, Heft 3 (8.6.2010), 1-8, 6.2010
- Creator
-
Rehnberg, Maria
- Contributor
-
Brisslert, Mikael
Amu, Sylvie
Zendjanchi, Kiandoht
Håwi, Gunilla
Bokarewa, Maria I.
SpringerLink (Online service)
- DOI
-
10.1186/ar3047
- URN
-
urn:nbn:de:1111-2016050315802
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rehnberg, Maria
- Brisslert, Mikael
- Amu, Sylvie
- Zendjanchi, Kiandoht
- Håwi, Gunilla
- Bokarewa, Maria I.
- SpringerLink (Online service)
Other Objects (12)
Seronegative and seropositive rheumatoid arthritis treated with rituximab
A rheumatoid factor paradox: inhibition of rituximab effector function
Analyse der Rituximab-induzierten Immunität gegen DLBCL-assoziierte Antigene
Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas
The development of antibodies against tumour-associated carbohydrate antigens
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
Carbohydrate-functionalized nanocarriers for the selective targeting of antigen presenting cells
Prognostic significance of carbohydrate antigen 125 in stage D heart failure
Seronegative and seropositive rheumatoid arthritis treated with rituximab
A rheumatoid factor paradox: inhibition of rituximab effector function
Analyse der Rituximab-induzierten Immunität gegen DLBCL-assoziierte Antigene
Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas
The development of antibodies against tumour-associated carbohydrate antigens
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
Carbohydrate-functionalized nanocarriers for the selective targeting of antigen presenting cells
Prognostic significance of carbohydrate antigen 125 in stage D heart failure
Seronegative and seropositive rheumatoid arthritis treated with rituximab
A rheumatoid factor paradox: inhibition of rituximab effector function
Analyse der Rituximab-induzierten Immunität gegen DLBCL-assoziierte Antigene
Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas
The development of antibodies against tumour-associated carbohydrate antigens
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
Carbohydrate-functionalized nanocarriers for the selective targeting of antigen presenting cells